NCT06996119View on ClinicalTrials.gov

Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

May 25, 2026

Primary Completion Date

May 25, 2027

Study Completion Date

May 25, 2027

Conditions
Acute Myeloid LeukemiaGraft Versus Host DiseaseMyelodysplastic Syndrome
Interventions
PROCEDURE

Biospecimen Collection

Undergo blood sample collection

DRUG

Busulfan

Given IV

PROCEDURE

Computed Tomography

Undergo chest CT

DRUG

Cyclophosphamide

Given IV

PROCEDURE

Echocardiography Test

Undergo ECHO

BIOLOGICAL

Emapalumab

Given IV

DRUG

Fludarabine

Given IV

PROCEDURE

Hematopoietic Cell Transplantation

Given infusion

DRUG

Melphalan

Given IV

PROCEDURE

Multigated Acquisition Scan

Undergo MUGA

DRUG

Mycophenolate Mofetil

Given IV or PO

OTHER

Questionnaire Administration

Ancillary studies

DRUG

Tacrolimus

Given IV or PO

Trial Locations (1)

91010

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER